Core Viewpoint - Tiger Med's stock price has shown significant growth in recent months, with a year-to-date increase of 13.28% and a 30.31% rise over the past 20 trading days [1]. Group 1: Stock Performance - As of January 14, Tiger Med's stock price reached 64.23 CNY per share, with a trading volume of 1.49 billion CNY and a market capitalization of 55.304 billion CNY [1]. - The stock experienced a 2.11% increase during the trading session on January 14 [1]. - The stock has seen a 6.52% increase over the last five trading days and an 18.77% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the last three years [3]. - The second-largest shareholder, Hong Kong Central Clearing Limited, increased its holdings by 25.097 million shares to 48.3625 million shares [3].

来源：新浪证券-红岸工作室 1月13日，中国东航涨0.50%，成交额5.95亿元。两融数据显示，当日中国东航获融资买入额2478.48万 元，融资偿还5368.68万元，融资净买入-2890.19万元。截至1月13日，中国东航融资融券余额合计2.60 亿元。 融资方面，中国东航当日融资买入2478.48万元。当前融资余额2.55亿元，占流通市值的0.25%，融资余 额低于近一年10%分位水平，处于低位。 分红方面，中国东航A股上市后累计派现32.96亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，中国东航十大流通股东中，中国证券金融股份有限公司位居第八 大流通股东，持股4.30亿股，持股数量较上期不变。香港中央结算有限公司位居第十大流通股东，持股 2.95亿股，相比上期减少545.24万股。 资料显示，中国东方航空股份有限公司位于上海市闵行区虹翔三路36号,香港金钟道95号统一中心19楼D 室，成立日期1995年4月14日，上市日期1997年11月5日，公司主营业务涉及航空客、货、邮、行李运输 业务及延伸服务;通用航空业务;航空器维修;航空设备制造与维修;国内外航空公司的代理业务。 ...

证券时报·数据宝统计，截至发稿，广电运通收盘价为13.65元，下跌2.64%，本期筹码集中以来股价累 计下跌1.16%。具体到各交易日，4次上涨，4次下跌。 融资融券数据显示，该股最新（1月13日）两融余额为14.31亿元，其中，融资余额为14.29亿元，本期筹 码集中以来融资余额合计减少6967.38万元，降幅为4.65%。 广电运通1月14日披露，截至2026年1月10日公司股东户数为97141户，较上期（2025年12月31日）减少 9102户，环比降幅为8.57%。 公司发布的三季报数据显示，前三季公司共实现营业收入79.06亿元，同比增长11.08%，实现净利润 6.02亿元，同比下降10.51%，基本每股收益为0.2400元，加权平均净资产收益率4.77%。（数据宝） （文章来源：证券时报网） ...

机构持仓方面，截止2025年9月30日，卓胜微十大流通股东中，香港中央结算有限公司位居第四大流通 股东，持股1006.88万股，相比上期增加95.86万股。易方达创业板ETF（159915）位居第九大流通股 东，持股730.24万股，相比上期减少124.61万股。华泰柏瑞沪深300ETF（510300）位居第十大流通股 东，持股633.45万股，相比上期减少29.73万股。 资料显示，江苏卓胜微电子股份有限公司位于江苏省无锡市滨湖区胡埭工业园刘闾路29号，成立日期 2012年8月10日，上市日期2019年6月18日，公司主营业务涉及射频集成电路领域的研究、开发、生产与 销售。主营业务收入构成为：商品销售收入99.08%，其他(补充)0.49%，IP授权及服务0.37%，权利金 0.06%。 截至12月31日，卓胜微股东户数7.62万，较上期减少2.09%；人均流通股5884股，较上期增加2.13%。 2025年1月-9月，卓胜微实现营业收入27.69亿元，同比减少17.77%；归母净利润-1.71亿元，同比减少 140.13%。 分红方面，卓胜微A股上市后累计派现8.84亿元。近三年，累计派现2.65亿元。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事、高级管理人员保证信息披露的内容真实、准确、完整、及时，没有虚假记载、误导 性陈述或重大遗漏。 经上海证券交易所（以下简称"上交所"）审核同意，重庆至信实业股份有限公司（以下简称"至信股 份""发行人"或"公司"）人民币普通股股票将于２０２６年１月１５日在上交所主板上市，上市公告书 全文和首次公开发行股票的招股说明书全文披露于上交所网站（ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ）和符 合中国证券监督管理委员会规定条件的网站（中国证券网：ｈｔｔｐｓ：／／ｗｗｗ．ｃｎｓｔｏｃ ｋ．ｃｏｍ；中证网：ｈｔｔｐｓ：／／ｗｗｗ．ｃｓ．ｃｏｍ．ｃｎ；证券时报网：ｈｔｔｐｓ：／ ／ｗｗｗ．ｓｔｃｎ．ｃｏｍ；证券日报网：ｈｔｔｐ：／／ｗｗｗ．ｚｑｒｂ．ｃｎ；经济参考网： ｈｔｔｐ：／／ｗｗｗ．ｊｊｃｋｂ．ｃｎ），并置备于发行人、上交所、本次发行保荐人（主承销 商）申万宏源证券承销保荐有限责任公司、联席主承销商西南证券股份有限公司的住所，供投资者查 阅。 公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初期的投资风险，广大投资者应充 分了解风险、理性参与新股交易 ...

Group 1 - The A-share market has shown a strong upward trend since the beginning of 2026, with the financing balance of the two markets exceeding 2.6 trillion yuan, prompting leading brokerage firms to issue bonds to support business development [1][3] - Major brokerages have actively engaged in bond issuance, with China Galaxy announcing a public bond issuance of up to 30 billion yuan and East Money Securities planning to issue up to 20 billion yuan in subordinated bonds [1][3] - The bond financing scale for brokerages has experienced explosive growth, with a total issuance amount of 81.3 billion yuan in early 2026, a nearly 70% increase compared to the same period in 2025 [3][4] Group 2 - The surge in bond financing is driven by a combination of factors, including increased market activity, rising capital demands, and a favorable low-interest-rate environment that makes bond financing more attractive than equity financing [6][7] - Brokerages are using the proceeds from bond issuances primarily for replenishing working capital and repaying maturing debts, which is crucial for their operational stability and growth [5][6] - The trend of bond issuance is expected to continue in 2026, with a focus on capital supplement bonds and a shift towards longer-term financing to match the capital needs of margin trading and proprietary investment [8][9]

本报讯 （记者王宁）新一批"两融标的"名单正式出炉。1月12日，沪深交易所对融资融券标的进行新一 轮调整，其中科创债ETF嘉实（159600）连续入选深交所两融名单，成为深市唯一的科创债两融标的； 同时，也是今年一季度深交所和上交所中两市唯一的科创债ETF两融标的。 长期以来，证券交易所通常会在每季度末对两融标的进行评估及调整，维持两融资格需要满足一定的流 动性、规模和市场表现要求。分析人士认为，科创债ETF嘉实（159600）能够持续入选这一资格，反映 出其在市场规模、流动性和市场表现方面等环节均达到了交易所的标准。 数据显示，截至目前，科创债ETF嘉实（159600）自上市以来日均成交额在70亿元以上，交投持续活 跃，该产品规模持续位居同标的第一。同时，该ETF已成功纳入回购质押库，力争在风险可控前提下优 化投资收益。 嘉实基金相关人士表示，科创债ETF的推出，标志着我国债券市场正式迎来"科技板"时代。作为高效、 透明、低门槛的指数化投资工具，科创债ETF不仅为投资者提供了参与国家科技创新战略的新路径，也 有效引导金融资源精准滴灌前沿科技产业，助力科技型企业高质量发展。随着政策支持力度加大、发行 主体扩容 ...

资金流向方面，今日该股主力资金净流出3.35亿元，其中，特大单净流出1.08亿元，大单资金净流出 2.28亿元。近5日主力资金净流入2.19亿元。 大位科技(600589)今日下跌4.17%，全天换手率29.08%，成交额43.81亿元，振幅16.24%。龙虎榜数据显 示，沪股通净买入429.30万元，营业部席位合计净卖出7836.58万元。 上交所公开信息显示，当日该股因日换手率达29.08%上榜，沪股通净买入429.30万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交11.62亿元，其中，买入成交额为5.44亿 元，卖出成交额为6.18亿元，合计净卖出7407.28万元。 具体来看，今日上榜的营业部中，沪股通为第一大买入营业部及第一大卖出营业部，买入金额为2.30亿 元，卖出金额为2.26亿元，合计净买入429.30万元。 近半年该股累计上榜龙虎榜5次，上榜次日股价平均涨1.75%，上榜后5日平均涨1.88%。 （文章来源：证券时报网） 融资融券数据显示，该股最新（1月12日）两融余额为8.61亿元，其中，融资余额为8.61亿元，融券余额 为36.33万元。近5日融资余额合计增加3.90亿 ...

Core Viewpoint - Starshine Technology's stock experienced a decline of 3.82% on January 13, with a trading volume of 611 million yuan and a market capitalization of 26.42 billion yuan [1] Group 1: Company Overview - Starshine Technology Co., Ltd. is located at 16th Floor, No. 1, Houzhan Road, Tong'an District, Xiamen, Fujian Province, and was established on December 21, 2017, with its IPO on March 28, 2024 [3][7] - The company's main business involves the design, research, and sales of edge AI SoC chips, primarily for smart security, IoT, automotive applications, and other ICs [3][7] - As of December 31, the number of shareholders was 31,900, a decrease of 4.22%, with an average of 5,858 circulating shares per person, an increase of 4.41% [7] Group 2: Financial Performance - For the period from January to September 2025, Starshine Technology achieved a revenue of 2.166 billion yuan, representing a year-on-year growth of 19.50%, and a net profit attributable to shareholders of 202 million yuan, up 3.03% year-on-year [7] - The company has distributed a total of 126 million yuan in dividends since its A-share listing [8] Group 3: Market Activity - The stock has seen a net outflow of 60.31 million yuan from major investors today, with a continuous reduction in major funds over the past three days [4][5] - The average trading cost of the stock is 60.93 yuan, with the current price near a support level of 61.95 yuan, indicating potential for a rebound if it holds above this level [6] Group 4: Strategic Developments - The company has developed chips suitable for AI glasses and has begun shipping to end customers, while also engaging with various clients including mobile brands and startups [2] - Starshine Technology has invested 10 million yuan in Nanjing Qipao Electronic Technology Co., Ltd., acquiring a 4% stake, focusing on ultra-low power consumption chips for smart wearables [2] - The company is enhancing its AI processor IP capabilities to improve processing power and algorithm efficiency, which will support various customer-specific applications [3]

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, but benefits from its overseas sales and the depreciation of the RMB [1][3]. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue sources for Canar Medical are syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of December 31, the number of shareholders is 7,184, a decrease of 3.12% from the previous period, while the average circulating shares per person increased by 3.22% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On January 13, the stock price of Canar Medical fell by 0.62%, with a trading volume of 120 million yuan and a turnover rate of 5.46%, resulting in a total market capitalization of 3.549 billion yuan [1]. - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. Group 4: Technical Analysis - The average trading cost of the stock is 27.99 yuan, with recent interest in the stock leading to increased concentration of holdings. The current stock price is near a resistance level of 29.73 yuan, indicating potential for a price correction if it does not break through this level [6].